Myocardial Ischemia Market Report 2026

Myocardial Ischemia Market Overview

• Myocardial Ischemia market size has reached to $0.84 billion in 2025 • Expected to grow to $1.14 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: Diabetes Epidemic Fuels Myocardial Ischemia Market Growth • Market Trend: Innovative Approaches In Myocardial Ischemia Treatment With FDA Approval of Lodoco (Colchicine) Highlights New Era In Cardiovascular Care • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Myocardial Ischemia Market?

Myocardial ischemia, also known as cardiac ischemia, is a condition characterized by reduced blood flow to the heart muscle. This reduction in blood flow leads to inadequate oxygen and nutrient delivery to the heart, potentially causing damage to the heart muscle. The most common cause of myocardial ischemia is the buildup of plaque in the coronary arteries, which restricts blood flow. The main types of myocardial ischemia are symptomatic and asymptomatic. Symptomatic myocardial ischemia refers to cases where the individual experiences symptoms such as chest pain or discomfort, also known as angina, during episodes of reduced blood flow to the heart muscle. The various treatments and diagnoses include diagnosis, treatments that are used by various end-users such as hospitals and clinics, diagnostic centers, and ambulatory surgery centers.

What Is The Myocardial Ischemia Market Growth Forecast?

The myocardial ischemia market size is expected to see strong growth in the next few years. It will grow to $1.14 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to advancements in imaging technologies, growing adoption of precision medicine, expansion of preventive cardiology programs, increasing investment in cardiac r&d, rising demand for minimally invasive treatments. Major trends in the forecast period include growing adoption of advanced cardiac imaging technologies, rising preference for minimally invasive cardiac interventions, increasing use of combination drug therapies, greater focus on preventive cardiology and early risk screening, high demand for personalized cardiac treatment plans.

Global Myocardial Ischemia Market Segmentation

1) By Type: Symptomatic, Asymptomatic 2) By Treatment And Diagnosis: Diagnosis, Treatment 3) By End User: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgery Centers Subsegments: 1) By Symptomatic: Acute Myocardial Ischemia, Chronic Myocardial Ischemia, Stable Angina, Unstable Angina 2) By Asymptomatic: Silent Myocardial Ischemia, Exercise-Induced Asymptomatic Ischemia

What Is The Driver Of The Myocardial Ischemia Market?

The rising incidence of diabetes is expected to propel the growth of the myocardial ischemia market going forward. Diabetes refers to a group of metabolic disorders that involve the body's inability to produce or effectively use insulin, a hormone produced by the pancreas that regulates blood sugar levels. The rising incidence of diabetes is due to obesity and severe obesity, a lack of physical activity, and genetic factors. The growing prevalence of diabetes contributes to the higher incidence of myocardial ischemia, leading to increased demand for diagnostic, therapeutic, and management solutions for myocardial ischemia. For instance, in April 2023, according to a report published by The British Diabetic Association, a UK-based diabetes charity, 4.3 million individuals in the UK were diagnosed with diabetes. Registration data for 2021-22 shows an increase of 148,951 cases compared to 2020-21. Additionally, over 2.4 million people in the UK are at high risk of developing type 2 diabetes. The rising incidence of diabetes is driving the growth of the myocardial ischemia industry.

Key Players In The Global Myocardial Ischemia Market

Major companies operating in the myocardial ischemia market are Cardinal Health Inc., Pfizer Inc., Roche Holding AG, Bayer AG, Sanofi SA, Novartis AG, Bristol‑Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories Inc., Eli Lilly and Company, Medtronic Plc, Boehringer Ingelheim International GmbH, Siemens Healthineers AG, Merck KGaA, GE HealthCare Technologies Inc., Fujifilm Holdings Corporation, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Canon Medical Systems Corporation, Johnson & Johnson, Koninklijke Philips NV, Biotronik SE & Co KG, Edwards Lifesciences Corporation, Teva Pharmaceutical Industries Ltd, Schiller AG, AliveCor Inc.

Global Myocardial Ischemia Market Trends and Insights

Major companies operating in the myocardial ischemia market are developing innovative drugs such as Lodoco (colchicine) to reduce inflammation and lower the risk of cardiovascular events in patients with coronary artery disease. Lodoco is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease. For instance, in June 2023, Agepha Pharma, a US-based pharmaceutical company, launched Lodoco (colchicine), approved by the Food and Drug Administration, a US-based government agency. This approval marks the first FDA-approved treatment targeting cardiovascular inflammation. It is based on data from the LoDoCo2 trial, which demonstrated a 31% relative reduction in the risk of cardiovascular events with colchicine 0.5 mg once daily compared to placebo. Lodoco is prescribed to lower the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or multiple cardiovascular risk factors.

What Are Latest Mergers And Acquisitions In The Myocardial Ischemia Market?

In March 2024, Novo Nordisk A/S, a Denmark-based pharmaceutical company, acquired Cardior Pharmaceuticals for €1.025 billion ($1.10 billion). Novo Nordisk plans to leverage Cardior's expertise and ongoing clinical programs to accelerate the development of CDR132L and expand its offerings in this critical therapeutic area. Cardior Pharmaceuticals is a Germany-based biopharmaceutical company that offers drugs for myocardial ischemia.

Regional Outlook

North America was the largest region in the myocardial ischemia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Myocardial Ischemia Market?

The myocardial ischemia market consists of sales of statin, anticoagulants, and antiplatelet agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Myocardial Ischemia Market Report 2026?

The myocardial ischemia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the myocardial ischemia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.